What Researchers Did
Researchers evaluated the safety and efficacy of combining carmustine wafers and permanent iodine-125 seed implants after tumor resection in 34 patients with recurrent glioblastoma multiforme.
What They Found
The median survival period was 69 weeks, with a 12-month survival rate of 66%, while the median progression-free survival was 47 weeks, with a 12-month rate of 32%. Brain necrosis occurred in 8 patients (24%) but was successfully managed with surgery or hyperbaric oxygen therapy.
What This Means for Canadian Patients
This combined treatment approach of carmustine wafers and iodine-125 seeds following tumor resection may offer a promising option for Canadian patients with recurrent glioblastoma multiforme. Patients should discuss these localized adjunct therapies with their neuro-oncology team to understand potential benefits and risks for their specific situation.
Canadian Relevance
This study was not conducted in Canada and does not have a direct Canadian connection.
Study Limitations
A limitation of this study is the relatively small sample size of 34 patients and the lack of a randomized control group.